PALI vs. FRTX, CELZ, TTNP, TCON, FNCH, KRBP, ALBT, ELOX, PSTV, and GMDAQ
Should you be buying Palisade Bio stock or one of its competitors? The main competitors of Palisade Bio include Fresh Tracks Therapeutics (FRTX), Creative Medical Technology (CELZ), Titan Pharmaceuticals (TTNP), TRACON Pharmaceuticals (TCON), Finch Therapeutics Group (FNCH), Kiromic BioPharma (KRBP), Avalon GloboCare (ALBT), Eloxx Pharmaceuticals (ELOX), Plus Therapeutics (PSTV), and Gamida Cell (GMDAQ). These companies are all part of the "medical" sector.
Fresh Tracks Therapeutics (NASDAQ:FRTX) and Palisade Bio (NASDAQ:PALI) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, community ranking, profitability, valuation, institutional ownership, risk, dividends, earnings and analyst recommendations.
Fresh Tracks Therapeutics has higher revenue and earnings than Palisade Bio. Fresh Tracks Therapeutics is trading at a lower price-to-earnings ratio than Palisade Bio, indicating that it is currently the more affordable of the two stocks.
25.0% of Fresh Tracks Therapeutics shares are held by institutional investors. Comparatively, 11.8% of Palisade Bio shares are held by institutional investors. 0.2% of Fresh Tracks Therapeutics shares are held by company insiders. Comparatively, 2.2% of Palisade Bio shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Palisade Bio has a net margin of 0.00% compared to Palisade Bio's net margin of -91.29%. Palisade Bio's return on equity of -60.83% beat Fresh Tracks Therapeutics' return on equity.
Palisade Bio has a consensus price target of $131.25, indicating a potential upside of 1,561.39%. Given Fresh Tracks Therapeutics' higher probable upside, analysts clearly believe Palisade Bio is more favorable than Fresh Tracks Therapeutics.
Palisade Bio received 8 more outperform votes than Fresh Tracks Therapeutics when rated by MarketBeat users. Likewise, 44.44% of users gave Palisade Bio an outperform vote while only 0.00% of users gave Fresh Tracks Therapeutics an outperform vote.
Fresh Tracks Therapeutics has a beta of 0.35, indicating that its share price is 65% less volatile than the S&P 500. Comparatively, Palisade Bio has a beta of 1.25, indicating that its share price is 25% more volatile than the S&P 500.
In the previous week, Palisade Bio had 10 more articles in the media than Fresh Tracks Therapeutics. MarketBeat recorded 10 mentions for Palisade Bio and 0 mentions for Fresh Tracks Therapeutics. Fresh Tracks Therapeutics' average media sentiment score of 0.29 beat Palisade Bio's score of 0.00 indicating that Palisade Bio is being referred to more favorably in the news media.
Summary
Palisade Bio beats Fresh Tracks Therapeutics on 11 of the 17 factors compared between the two stocks.
Get Palisade Bio News Delivered to You Automatically
Sign up to receive the latest news and ratings for PALI and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding PALI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Palisade Bio Competitors List
Related Companies and Tools
